Morgan Stanley Aravive, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.11 - $0.22 $330 - $660	3,000 New	3,000 $0
Q4 2023 Feb 13, 2024	SELL	$0.11 - $0.22 $1,980 - $3,960	-18,001 Reduced 85.69%	3,005 $0
Q3 2023 Nov 15, 2023	SELL	$0.11 - $1.76 $6,929 - $110,878	-62,999 Reduced 74.99%	21,006 $2,000
Q2 2023 Aug 14, 2023	SELL	$1.25 - $1.92 $11,977 - $18,397	-9,582 Reduced 10.24%	84,005 $105,000
Q1 2023 May 15, 2023	BUY	$1.29 - $2.46 $18,699 - $35,660	14,496 Added 18.33%	93,587 $187,000
Q4 2022 Feb 14, 2023	SELL	$1.2 - $1.83 $22,825 - $34,808	-19,021 Reduced 19.39%	79,091 $104,000
Q3 2022 Nov 14, 2022	SELL	$0.61 - $1.03 $3,659 - $6,178	-5,999 Reduced 5.76%	98,112 $80,000
Q2 2022 Oct 27, 2022	BUY	$0.93 - $1.9 $34,932 - $71,367	37,562 Added 56.44%	104,111 $103,000
Q2 2022 Aug 15, 2022	BUY	$0.93 - $1.9 $34,932 - $71,367	37,562 Added 56.44%	104,111 $103,000
Q1 2022 Oct 27, 2022	SELL	$1.85 - $2.75 $69,489 - $103,295	-37,562 Reduced 36.08%	66,549 $128,000
Q1 2022 May 13, 2022	SELL	$1.85 - $2.75 $3,174 - $4,719	-1,716 Reduced 2.51%	66,549 $128,000
Q4 2021 Feb 14, 2022	BUY	$2.19 - $4.07 $60,179 - $111,839	27,479 Added 67.37%	68,265 $150,000
Q3 2021 Nov 15, 2021	BUY	$3.67 - $5.8 $149,684 - $236,558	40,786 New	40,786 $151,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.